Hepatology Highlights

Omar Y. Mousa, Harmeet Malhi, Nicholas Russo, Arun Jesudian, Joseph F. Pisa, Tasha B. Kulai, Jessica L. Maiers, Enis Kostallari, Nidhi Jalan‐Sakrikar, Zaid H. Tafesh, Brett E. Fortune, Lauren Yang, Daryl T.Y. Lau, Kavitha Nair, Joel Wedd – 28 June 2019

Hepatology Highlights

Jaspreet S. Suri, Ghideon Ezaz, Daryl T.Y. Lau, Tasha B. Kulai, Harmeet Malhi, Zaid H. Tafesh, Brett Fortune, Russell Rosenblatt, Robert S. Brown, Joseph F. Pisa, Nicholas Russo, Petra Hirsova, Robert E. Schwartz, Sayed Obaidullah Aseem, Nidhi Jalan‐Sakrikar, Vikas Gupta – 28 June 2019

Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma

Pimwipa Ueasilamongkol, Tanaporn Khamphaya, Mateus T. Guerra, Michele A. Rodrigues, Dawidson A. Gomes, Yong Kong, Wei Wei, Dhanpat Jain, David C. Trampert, Meenakshisundaram Ananthanarayanan, Jesus M. Banales, Lewis R. Roberts, Farshad Farshidfar, Michael H. Nathanson, Jittima Weerachayaphorn – 28 June 2019 – Cholangiocarcinoma (CCA) is the second most common malignancy arising in the liver. It carries a poor prognosis, in part because its pathogenesis is not well understood.

Associations Between Body Fat, Muscle Mass, and Nonalcoholic Fatty Liver Disease: A Population‐Based Study

Julianna C. Hsing, Mindie H. Nguyen, Baiyu Yang, Yan Min, Summer S. Han, Emily Pung, Sandra J. Winter, Xueyin Zhao, Da Gan, Ann W. Hsing, Shankuan Zhu, C. Jason Wang – 27 June 2019 – Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of liver disease worldwide and has emerged as a significant public health concern in China. A better understanding of the etiology of NAFLD can inform effective management strategies for this disease.

Hepatology Highlights

Omar Y. Mousa, Harmeet Malhi, Nicholas Russo, Arun Jesudian, Joseph F. Pisa, Tasha B. Kulai, Jessica L. Maiers, Enis Kostallari, Nidhi Jalan‐Sakrikar, Zaid H. Tafesh, Brett E. Fortune, Lauren Yang, Daryl T.Y. Lau, Kavitha Nair, Joel Wedd – 27 June 2019

Subscribe to